Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors.

Sogabe, Satoshi; Kawakita, Youichi; Igaki, Shigeru; Iwata, Hidehisa; Miki, Hiroshi; Cary, Douglas R; Takagi, Terufumi; Takagi, Shinji; Ohta, Yoshikazu; Ishikawa, Tomoyasu

Sogabe, Satoshi; Kawakita, Youichi; Igaki, Shigeru; Iwata, Hidehisa; Miki, Hiroshi; Cary, Douglas R; Takagi, Terufumi; Takagi, Shinji; Ohta, Yoshikazu; Ishikawa, Tomoyasu.

Afiliación

Sogabe S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Kawakita Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Igaki S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Iwata H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Miki H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Cary DR; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Takagi T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Takagi S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Ohta Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Ishikawa T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

ACS Med Chem Lett ; 4(2): 201-5, 2013 Feb 14.

Article en En | MEDLINE | ID: mdl-24900643

Palabras clave

EGFR T790/L858 mutant inhibitors; NSCLC; TAK-285; crystal structure; drug sensitivity and resistance; pyrrolo[3,2-d]pyrimidine derivatives

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2013 Tipo del documento: Article País de afiliación: Japón